30 closest matches · ranked by relevance
Female Sexual Arousal Disorder · Hypoactive Sexual Desire Disorder
Primary: The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE) — 0.2; 0.6; 0.7; 0.8 SSEs — p=<0.05
Female Sexual Dysfunction
Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109
Sexual Dysfunctions, Psychological
Primary: Satisfying Sexual Event Monthly Change From Baseline at Final Visit — 0.8; 1.4; 1.6 number of events — p=0.0454
Sexual Dysfunctions, Psychological
Primary: The Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain. — 1.0; 0.7 units on a scale
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Number of Satisfying Sexual Events — 1.0; 0.6 sexual events
Hypoactive Sexual Desire Disorder
Primary: Changes in Blood Oxygen Level Dependent (BOLD) Signal Change on Functional MRI — 9.98; 7.67 BOLD signal change
Sexual Dysfunctions, Psychological
Primary: Flibanserin: Area Under the Curve; AUC_0-∞ — 2570 ng*h/mL
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary. — 1.4; 1.4; 1.9; 1.1 SSEs per 28 days
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary. — 1.2; 1.5; 0.9 events per month
Female Orgasmic Disorder
Primary: Number of Orgasms Over an 84 Day Period Compared to Placebo Over the Entire Treatment Period — 2.8; 3.9; 3.2; 1.9 orgasms
Sexual Dysfunctions, Psychological
Primary: Mean Change From Baseline to 24 Weeks in the Frequency of Satisfying Sexual Events as Measured by the eDiary. — 1.5; 1.6; 1.6; 1.6 SSEs per week
Female Sexual Dysfunction
Primary: Female Sexual Function Index (FSFI) — 16.72; 16.88; 22.02; 21.22 score on a scale
Hypoactive Sexual Desire Disorder
Primary: Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall. — 0.54; 0.24; 1.30; 0.77 score on a scale
Hypoactive Sexual Desire Disorder · Sexual Dysfunction · Female Sexual Dysfunction
Primary: Feasibility - Number of Enrolled Women Participating in All Sessions — 15; 22 Participants — p=0.027
Hypoactive Sexual Desire Disorder
Primary: Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall. — 0.63; 0.21; 1.25; 0.70 score on a scale
Sexual Dysfunctions, Psychological
Primary: Frequency of Adverse Events — 331; 206; 58; 51 participants with any adverse event
Contraception · Libido
Primary: Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS) — 6.45; 5.98 scores on a scale
Female Sexual Dysfunction · Female Sexual Dysfunction Due to Physical Condition
Primary: Maximum Percent Change in Vaginal Pulse Amplitude (VPA) From the Average Baseline Value — 119.8; 94.3; 135.4; 113.5 percent change of VPA
Low Female Sexual Desire
Primary: Female Sexual Distress Scale-Revised (FSDS-R) — 22.88; 25.68; 23.02; 23.87 units on a scale
Female Sexual Dysfunction · Anorgasmia
Primary: Clitoral Measurements Using Pelvic MRI — 51.3; 45.1; 29.4; 20.6 millimeters (mm)
Female Sexual Dysfunction · Polycystic Ovary Syndrome
Primary: Sexual Function — 24.8; 26.0 score on a scale — p=0.71
Sexual Dysfunction, Physiological · Body Image · Libido; Loss, Aversion
Primary: Screen Failure Rate (a Measure of Feasibility) — 36 Participants
Breast Cancer · Vaginal Dryness · Dyspareunia
Primary: Total Female Sexual Function Index (FSFI) Score — 8.691; 18.783 units on a scale — p=<0.0005
Depression
Primary: Depressive Symptom Severity — 15.3; 14.1 units on a scale
Healthy
Primary: Change in 17-OH Pregnenolone — 120; 158; 171; 170 ng/dl — p=>0.8
Hypertension · Female Sexual Dysfunction
Primary: Change in Female Sexual Function Index — 1.24; 1.42 units on a scale
Dyspareunia
Primary: Change in Median Dyspareunia Pain Scores After 4 Weeks Using Study Drug — -1.5; -3 score on a scale — p=0.08
Female Sexual Dysfunction · Spinal Cord Injuries
Primary: Percent Change in Average Vaginal Pulse Amplitude (VPA) During Stimulation From the Average Baseline Value — 3.3; 3.5 Percent change
Treatment Outcome
Primary: Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8 — 8.8; 6.6 scores on a scale — p=0.013
Atrophy of Vagina · Menopause · Dyspareunia (Female)
Primary: Most Bothersome Symptom (MBS) Severity — -1.2; -1.0; -0.2; -1.4 units on a scale — p=0.25